9900174-5

Ref. Only

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 35/78

A1

(11) International Publication Number: WO 98/01144

(43) International Publication Date: 15 January 1998 (15.01.98)

(21) International Application Number: PCT/US97/12293

(22) International Filing Date: 9 July 1997 (09.07.97)

(30) Priority Data:

60/016,100	9 July 1996 (09.07.96)	US
60/021,467	10 July 1996 (10.07.96)	US

(71) Applicant: SAGE, R & D [US/US]; 4841 Nugent Drive, Columbus, OH 43220 (US).

(72) Inventors: TSAI, Hsiu-Hsien; 46 Chang-Shung Street, Chang-Huah (TW). HWANG, Shie-Ming; 4886 Chevy Chase Avenue, Columbus, OH 43220 (US).

(74) Agent: NICKEY, Donald, O.; Standley & Gilcrest, Suite 500, 555 Metro Place North, Dublin, OH 43017 (US).


(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: ANTIVIRAL AGENTS FROM PLANT EXTRACTS AND USE FOR TREATMENT OF VIRAL INFECTIONS



(57) Abstract

This invention relates to compositions derived from Chinese herbal medicines, medicinal plants and extracts thereof, and to their use for the treatment of animals infected with viruses, especially with hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). More specifically, the compositions of the present invention are derived from various Chinese herbal medicines or medicinal plants which have a long history of human consumption. The compositions of the invention are obtained through specific techniques and have demonstrated outstanding efficacy for treating human HBV carriers and hepatitis C patients. Compositions according to the invention have also exhibited *in vitro* antiviral activities against murine leukemia virus (MuLV) and HIV. HIV is the virus known to cause acquired immunodeficiency syndrome (AIDS) in humans and AIDS presents special problems to the medical community which the present invention addresses.